WO2021262562A3 - Méthodes de traitement du cancer ou de la maladie de von hippel-lindau à l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé - Google Patents

Méthodes de traitement du cancer ou de la maladie de von hippel-lindau à l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé Download PDF

Info

Publication number
WO2021262562A3
WO2021262562A3 PCT/US2021/038171 US2021038171W WO2021262562A3 WO 2021262562 A3 WO2021262562 A3 WO 2021262562A3 US 2021038171 W US2021038171 W US 2021038171W WO 2021262562 A3 WO2021262562 A3 WO 2021262562A3
Authority
WO
WIPO (PCT)
Prior art keywords
lenvatinib
hif
antagonist
von
pharmaceutically acceptable
Prior art date
Application number
PCT/US2021/038171
Other languages
English (en)
Other versions
WO2021262562A2 (fr
Inventor
Rodolfo Fleury Perini
Elaine M. PINHEIRO
Jaqueline WILLEMANN ROGERIO
Original Assignee
Merck Sharp & Dohme Corp.
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp., Eisai R&D Management Co., Ltd. filed Critical Merck Sharp & Dohme Corp.
Priority to US18/009,109 priority Critical patent/US20230250182A1/en
Priority to BR112022026086A priority patent/BR112022026086A2/pt
Priority to JP2022578934A priority patent/JP2023531930A/ja
Priority to EP21828207.7A priority patent/EP4168016A2/fr
Priority to AU2021297151A priority patent/AU2021297151A1/en
Priority to CN202180051960.9A priority patent/CN116406288A/zh
Priority to CA3183862A priority patent/CA3183862A1/fr
Priority to MX2022016410A priority patent/MX2022016410A/es
Priority to KR1020237002564A priority patent/KR20230026492A/ko
Publication of WO2021262562A2 publication Critical patent/WO2021262562A2/fr
Publication of WO2021262562A3 publication Critical patent/WO2021262562A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes de traitement du cancer (par exemple un hypernéphrome) ou de la maladie de von Hippel-Lindau, qui comprend l'administration à un patient humain qui en a besoin : (a) d'un antagoniste de PD-1; (b) d'un inhibiteur de HIF-2α; et (c) de lenvatinib, ou d'un sel pharmaceutiquement acceptable associé. L'invention concerne également des kits contenant de tels agents et des utilisations de combinaisons thérapeutiques desdits agents pour le traitement du cancer.
PCT/US2021/038171 2020-06-17 2021-06-21 Méthodes de traitement du cancer ou de la maladie de von hippel-lindau à l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé WO2021262562A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US18/009,109 US20230250182A1 (en) 2020-06-22 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
BR112022026086A BR112022026086A2 (pt) 2020-06-22 2021-06-21 Métodos para tratar câncer ou doença de von-hippel lindau e para tratar carcinoma de célula renal, kit, e, uso de uma combinação terapêutica
JP2022578934A JP2023531930A (ja) 2020-06-22 2021-06-21 ＰＤ－１アンタゴニスト、ＨＩＦ－２α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法
EP21828207.7A EP4168016A2 (fr) 2020-06-17 2021-06-21 Méthodes de traitement du cancer ou de la maladie de von hippel-lindau à l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé
AU2021297151A AU2021297151A1 (en) 2020-06-17 2021-06-21 Methods for treating cancer or von-Hippel Lindau disease using a combination of a PD-1 antagonist, a HIF-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
CN202180051960.9A CN116406288A (zh) 2020-06-17 2021-06-21 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法
CA3183862A CA3183862A1 (fr) 2020-06-22 2021-06-21 Methodes de traitement du cancer ou de la maladie de von hippel-lindau a l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associ
MX2022016410A MX2022016410A (es) 2020-06-22 2021-06-21 Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
KR1020237002564A KR20230026492A (ko) 2020-06-22 2021-06-21 Pd-1 길항제, hif-2 알파 억제제 및 렌바티닙 또는 그의 제약상 허용되는 염의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063040225P 2020-06-17 2020-06-17
US63/040,225 2020-06-22
US202163146926P 2021-02-08 2021-02-08
US63/146,926 2021-02-08

Publications (2)

Publication Number Publication Date
WO2021262562A2 WO2021262562A2 (fr) 2021-12-30
WO2021262562A3 true WO2021262562A3 (fr) 2022-03-03

Family

ID=80322273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/038171 WO2021262562A2 (fr) 2020-06-17 2021-06-21 Méthodes de traitement du cancer ou de la maladie de von hippel-lindau à l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé

Country Status (4)

Country Link
EP (1) EP4168016A2 (fr)
CN (1) CN116406288A (fr)
AU (1) AU2021297151A1 (fr)
WO (1) WO2021262562A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
WO2023235236A1 (fr) * 2022-06-02 2023-12-07 Merck Sharp & Dohme Llc Méthodes de traitement du cancer, ou de la maladie de von hippel-lindau à l'aide d'une association d'un antagoniste de tigit, d'un antagoniste de pd-1 et d'un inhibiteur de hif-2-alpha

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017179739A1 (fr) * 2016-04-15 2017-10-19 Eisai R&D Management Co., Ltd. Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus
US20180021276A1 (en) * 2016-07-20 2018-01-25 Cipla Limited Bezafibrate for the treatment of cancer
WO2018031680A1 (fr) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Nouveaux composés, leurs utilisations et procédés de préparation
US20190209547A1 (en) * 2016-04-15 2019-07-11 Exelixis, Inc. Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017179739A1 (fr) * 2016-04-15 2017-10-19 Eisai R&D Management Co., Ltd. Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus
US20190209547A1 (en) * 2016-04-15 2019-07-11 Exelixis, Inc. Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
US20180021276A1 (en) * 2016-07-20 2018-01-25 Cipla Limited Bezafibrate for the treatment of cancer
WO2018031680A1 (fr) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Nouveaux composés, leurs utilisations et procédés de préparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ERIC JONASCH, FREDE DONSKOV, OTHON IIIOPOULOS, W. KIMRYN RATHMELL, VIVEK K. NARAYAN, BENJAMIN L. MAUGHAN, STEPHANE OUDARD, TOBIAS : "Belzutifan (MK-6482) for Von Hippel-Lindau Disease? Associated Renal Cell Carcinoma ", ASCO 2020 (AMERICAN SOCIETY OF CLINICAL ONCOLOGY), VIRTUAL SCIENTIFIC PROGRAM; MAY 29-31, 2020, 29 May 2020 (2020-05-29) - 31 May 2020 (2020-05-31), US, pages 1 - 28, XP009535918 *
J. MCDERMOTT, A. JIMENO: "Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer", DRUGS OF TODAY, vol. 51, no. 1, 1 January 2015 (2015-01-01), ES , pages 7, XP055316850, ISSN: 1699-3993, DOI: 10.1358/dot.2015.51.1.2250387 *
LEE C. H.: "A phase 1 b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma", ANNALS OF ONCOLOGY, vol. 28, no. 5, 9 January 2017 (2017-01-09), NL , pages v295 - v296, XP055909919, ISSN: 0923-7534, DOI: 10.1093/annonc/mdx371 *

Also Published As

Publication number Publication date
EP4168016A2 (fr) 2023-04-26
AU2021297151A1 (en) 2023-02-09
WO2021262562A2 (fr) 2021-12-30
CN116406288A (zh) 2023-07-07
CN116406288A8 (zh) 2024-02-13

Similar Documents

Publication Publication Date Title
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
LU92642I2 (fr) Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2021262562A3 (fr) Méthodes de traitement du cancer ou de la maladie de von hippel-lindau à l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
AR048324A1 (es) Metodos para tratar infecciones por vih
WO2004045593A3 (fr) Polytherapie anticancereuse au moyen d'un compose anticancereux active par gst et d'un autre traitement anticancereux
HK1071310A1 (en) Combination therapy for the treatment of cancer
JP2020523354A5 (fr)
WO2020033838A3 (fr) Traitement du cancer à egfr mutant
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21828207

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2022578934

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3183862

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022026086

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20237002564

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021828207

Country of ref document: EP

Effective date: 20230123

ENP Entry into the national phase

Ref document number: 2021297151

Country of ref document: AU

Date of ref document: 20210621

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21828207

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112022026086

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221220